Loading…

Oil palm leaf protein hydrolysate and its novel peptides as alternative plant-based α-glucosidase inhibitors

Diabetes, particularly type II, is a global health concern, with current treatments like α-glucosidase inhibitors often causing gastrointestinal side effects. This study explored the antihyperglycemic potential of crude protein hydrolysate from oil palm leaves (OPL) as a plant-based α-glucosidase in...

Full description

Saved in:
Bibliographic Details
Published in:International journal of biological macromolecules 2025-02, Vol.291, p.138897, Article 138897
Main Authors: Hau, Eng Huan, Chew, Lye Yee, Yeo, Siok Koon, Owatworakit, Amorn, Teh, Soek Sin, Mah, Siau Hui
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Diabetes, particularly type II, is a global health concern, with current treatments like α-glucosidase inhibitors often causing gastrointestinal side effects. This study explored the antihyperglycemic potential of crude protein hydrolysate from oil palm leaves (OPL) as a plant-based α-glucosidase inhibitor. OPL protein hydrolysate was extracted under acidic, neutral, and alkaline conditions, and their α-glucosidase inhibitory activity was assessed. OPL hydrolysate obtained under neutral conditions for 2 h showed the highest inhibitory activity, comparable to the standard drug, acarbose. Bioassay-guided fractionation of the most potent extract revealed that peptides from sub-fractions C1 and C9 exhibited stronger inhibition, with IC50 values of 66.3 and 62.0 μg/mL, respectively. Seven novel peptides were identified from these fractions, and molecular docking confirmed stable interactions between these peptides and the α-glucosidase enzyme via hydrogen bonds and salt bridges. These findings suggest that OPL protein hydrolysate is a plant-based promising natural α-glucosidase inhibitor with potential as an antidiabetic agent. Future studies should focus on in vivo validation of its efficacy and safety for therapeutic use.
ISSN:0141-8130
1879-0003
1879-0003
DOI:10.1016/j.ijbiomac.2024.138897